Welcome to the iCAD Investors Page

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".

Investor Presentation

To access a copy of the investor presentation, please see below.

​Investor Presentation

Quick Links

• Corporate Profile

• Events & Webcasts

• Financial News/Events

• Leadership

• Reports & SEC Files

• Stock Quote

• Corporate Governance

Investor Relations

LifeSci Advisors

Jeremy Feffer
917-749-1494

jeremy@lifesciadvisors.com

Media Inquiries

iCAD Technology Innovation Day

Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.

Register to watch this recording on-demand

​Watch Replay

iCAD, Inc.
603.882.5200
pr@icadmed.com

iCAD is committed to corporate sustainability and to making a difference for our environment.

Recent Press Releases

November 30, 2020
iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

November 25, 2020
iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

November 24, 2020
iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

November 5, 2020
iCAD Reports Financial Results For Third Quarter And Nine Months Ended September 30, 2020

October 29, 2020
iCAD to Report Third Quarter 2020 Financial Results on Thursday, November 5

* See all Press Releases

Recent Events and Webcasts

November 5, 2020
4:30 pm ET
iCAD To Report Third Quarter 2020 Financial Results

September 1-4, 2020
11:00 am ET - Track 4
iCAD to Present at the LD Micro 500 Virtual Conference

August 4, 2020
4:30 pm ET
iCAD to Report Second Quarter 2020 Financial Results on Tuesday, August 4

 

© 2020, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.